After 23 days, we observed that the combination of anti-IL-1β and anti-PD-1 showed no significant difference in tumor size when compared to control, anti-IL-1β monotherapy, or anti-PD-1 monotherapy (Fig. 1B); however, combination therapy prolonged survival (Fig. 1C). Here, IL1B is linked to neoplasm.